

Serving Public Health in Senegal since 1896



- Senegalese Foundation
- Not-for-profit
- Of public interest







Public Health



Education & Training



Vaccine Manufacturing



Advancing Public Health in Africa





Unique regional and global value proposition in public health

Strength in 5 core public health activities



Biomanufacturing

Production of vaccines, diagnostics and, in the near term, reagents and therapeutics



Biomedical research and innovation

Research on multiple infectious and epidemic topics, and innovation on new products



Epidemic Intelligence & Outbreak response

Epidemiological surveillance, outbreak response, epidemic clinical trials, public health programs, etc.



Human Capital Development

Training of peers, technicians, outbreak workforce, masters, PhDs



Specialized and decentralized Laboratories

Biomedical, food and environment safety laboratory testing; vaccine administration Distinctive capability to produce yellow fever vaccines end-to-end in Africa – from drug substance to production and fill and finish. Expanding to vaccines for epidemics

1 of 5

vaccine manufacturers in Africa and the only diagnostics and vaccine manufacturer

3 new assets

Under construction for vaccines and diagnostics biomanufacturing

Knowledge and expertise to detect diseases and manage epidemic outbreaks in Africa

>25

African countries supported in outbreak management

7 out of the 11

key functions of a public health institute

Excellence in infectious disease research and education

10%

of Senegal's publications

1st

Francophone institute in Africa for research publications

+50


PhDs, masters and technicians trained in infectious disease related topics

Innovation at Institut Pasteur de Dakar









Epidemic diagnostics


Mobile Laboratories for Outbreak response

Rethinking sample transport

Manufacturing In Africa for Disease Immunization & Building Autonomy



Modular design



Assembly & & transport

Site installation







Fast start & operational excellence

\$220 m

Investment required

\$150 - 180 m

Expected revenues

300 m doses

Manufacturing capacity

200 FTE

New jobs created





Project MADIBA

The MADIBA project is an opportunity to manufacture and supply high quality, affordable and relevant vaccines for Africa in Senegal with IPD as a center of excellence

Components of the project

Drug Substance (DS): MADIBA require the capacity to make vaccines from scratch and as will require a vaccine substance production facility

Fill and Finish (FF): Given the urgency to increase supply of vaccines against Covid-19 in Africa, the priority is for the new facility to be equipped and able to Fill & Finish bulk vaccine of a WHO approved COVID vaccine

Technology: Innovative technology with dual options of pouches and vials

Vaccine commercialization: Vaccines produced will be marketed through purchase agreements to be signed with potential buyers (e.g. UNICEF, COVAX, ECOWAS etc.)

Phase / Horizon 1 Phase / Horizon 2 Phase / Horizon 3 Covid 19 vaccines Essential/Routine vaccines ACDC/CEPI priority pathogens




MADIBA and AfricAmaril vaccine manufacturing facilities






General Site

Modelling of the Drug Product facility




























Construction and Site Update



Infrastructure (layout and structure)



Modular
Structures
and
Filling Machine

Recent pictures







Details – Last Update

- MADIBA Building
 - Steel work completed
 - Exterior maconnery completed
 - Civil works on the basement ongoing
 - Interior work construction ongoing
 - Utilities construction ongoing
 - External spaces and streets ongoing
- Annex buildings construction ongoing
- QC building main civil works completed

- Keyplants modules installed in final position
- Assembly works ongoing



Thank you



https://www.pasteur.sn/

Joe.Fitchett@Pasteur.sn